Latest News and Press Releases

HMNC presented data showing distinct nelivaptan response patterns, supporting its precision, genetics-guided approach to treating depression.

FDA has cleared the new Magstim Rapid TMS system for research and clinical applications, now with FDA clearance in the U.S. for the treatment of pain.

MINNEAPOLIS, March 19, 2025 (GLOBE NEWSWIRE) -- Major depression impacts more than 5 million U.S. adolescents every year, and NIH data shows that 20% of those aged 12 to 16 have had at least one...

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial for Next-Gen Lithium Treatment of Major Depressive Disorder at Mass. General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder at Massachusetts General Hospital

UKCA Approves Magstim Horizon Inspire TMS for NHS & Private UK Clinics. UK Made System for Patient Treatment of MDD, OCD and Decreasing Anxiety.

FDA clears Magstim INSPIRE Transcranial Magnetic Stimulation TMS system to treat patients with Depression, OCD, Anxious Depression

WHITLAND, United Kingdom, July 07, 2023 (GLOBE NEWSWIRE) -- The advanced and FDA-cleared Magstim Horizon 3.0 transcranial magnetic stimulation (TMS) system is now UKCA registered and available for...

Tel Aviv, Israel / Vancouver, Canada, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on...

MINNEAPOLIS, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Magstim, a global leader in neuroscience research and Transcranial Magnetic Stimulation (TMS) solutions for mental health, announced today that the FDA...